Radiofrequency Ablation Effective For Small Renal Cell Carcinoma and Other Masses
March 11, 2010 — Researchers from the M. D. Anderson Cancer Center have reported that radiofrequency ablation (RFA) is effective treatment for patients with renal masses, including renal cell carcinoma (RCC). The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium March 5-7 in San Francisco.
Single-dose Neulasta® as Effective as Multiple-dose Neupogen® in Children with Sarcoma
March 11, 2010 — Researchers involved in an international multicenter randomized trial have reported that single-dose Neulasta® (pegfilgrastim) is as effective as multiple-dose Neupogen® (filagrastim) for support of children receiving intensive chemotherapy for previously treated sarcoma. The details of this study were published in the March 10, 2010 issue of the Journal of Clinical Oncology.
Updated Survival Data on Provenge® for Treatment of Hormone Refractory Prostate Cancer Presented
March 11, 2010 — Researchers affiliated with the IMPACT trial have reported that additional follow-up and more analyses demonstrate a clear survival advantage of Provenge® (sipuleucel-T) versus placebo in men with hormone-refractory prostate cancer. The details of this study were presented at the 2010 Genitourinary Cancers Symposium in San Francisco between March 5 and 7.
Select news items provided by Reuters Health